Interface (TILE) shares soared 5.1% in the last trading session to close at $25.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 24.9% loss over the past four weeks.Interface's stock rally is an extension of its strong execution under the One Interface strategy, which is driving sales growth and margin expansion. Interface is benefiting from strong healthcare and education demand, improved product mix and ongoing automation-le ...

Core Insights - Interface reported a record year in 2025 with all-time highs in net sales, adjusted operating income, and adjusted EBITDA, driven by broad-based regional and segment growth, price and volume gains across all product categories, and operational improvements [4][7] Financial Performance - For the full year 2025, Interface achieved net sales of $1.39 billion, a 5.4% increase year-over-year, with adjusted EBITDA of $217.9 million and adjusted EPS of $1.94, reflecting a 33% increase [7][17] - Fourth-quarter net sales were $349.4 million, up 4.3% as reported and 1.6% on a currency-neutral basis, with adjusted gross margin at 38.6%, up 169 basis points [13][14] Growth Drivers - Global healthcare billings increased by 21% year-over-year in 2025, while education billings rose by 8%, attributed to expanded offerings at more approachable price points [1] - The combined U.S. selling team model across carpet tile, LVT, and nora Rubber has enhanced cross-selling effectiveness, contributing to a 17% increase in global rubber billings [2] Strategic Initiatives - The "One Interface" strategy focuses on strengthening global functions to support local selling teams, improving commercial productivity, and expanding margins through global supply chain management [3] - Interface launched "noravant," a PVC-free rubber sheet platform, expected to contribute $5–10 million in 2026 and potentially $50–100 million over five years [6][9] Capital Allocation and Outlook - For 2026, Interface projects net sales of $1.42–$1.46 billion and capital expenditures of about $55 million, while also extending its debt and increasing the quarterly dividend to $0.03 per share [5][19] - The company entered 2026 with solid orders and a healthy backlog, up 7% year-to-date, despite macroeconomic uncertainties [19] Sustainability Efforts - Sustainability remains a central theme, with Interface offering low-carbon products and incorporating captured carbon in manufacturing processes, recognized in various sustainability rankings [12]

Core Insights - The record 2025 performance was driven by the One Interface strategy, which consolidated global functions to support local selling teams and enhanced commercial productivity [1] - The U.S. combined selling model facilitated effective cross-selling across carpet tile, LVT, and rubber, leading to a 17% increase in global rubber billings for the year [1] - Growth was broad-based across all regions and product categories, with both price and volume increases contributing to a 4% currency-neutral net sales rise [1] Strategic Focus - The strategic focus on health care and education segments yielded significant results, with global health care billings up 21% as the company captured a larger share of the hospital floor plate [1] - Operational efficiency gains were achieved through targeted investments in automation and robotics within U.S. carpet tile and nora rubber facilities, driving gross margin expansion to 39% [1] Product Innovation and Sustainability - Product innovation aimed at expanding the addressable market by offering collections at more approachable price points while maintaining premium design leadership [1] - Sustainability remains a core differentiator, with the company incorporating captured carbon into manufacturing and launching the industry's first cradle-to-gate carbon negative rubber prototype [1]

Financial Data and Key Metrics Changes - In 2025, the company achieved record net sales, Adjusted Operating Income, and Adjusted EBITDA, with currency-neutral net sales increasing by 4% year-over-year [4][14] - Full year net sales totaled $1.39 billion, up 5.4%, with currency-neutral net sales in the Americas increasing by 5.5% and in EAAA by 2.4% [21][22] - Adjusted gross profit margin increased to 39%, up 187 basis points, driven by favorable pricing and manufacturing efficiencies [22] - Adjusted EPS for the fourth quarter was $0.49, up 44.1% compared to $0.34 [19] Business Line Data and Key Metrics Changes - All three product categories (carpet tile, LVT, and nora Rubber) experienced growth in both price and volume [5] - Global rubber billings increased by 17% in 2025 compared to the prior year [6] - Healthcare billings were up 21% year-over-year, while education billings increased by 8% [14][15] Market Data and Key Metrics Changes - In the Americas, currency-neutral net sales increased by 5% year-over-year, particularly strong in healthcare and education segments [14] - EAAA region saw a 2% increase in currency-neutral net sales, reflecting improving trends despite a challenging macro environment [14] - Corporate office billings were slightly up, with a focus on Class A spaces [15] Company Strategy and Development Direction - The company is committed to the "One Interface" strategy, focusing on global functions to support local selling teams and enhancing commercial productivity [4] - Continued investments in automation and robotics are expected to drive productivity gains and margin expansion [7][8] - The launch of Noravant, a new rubber flooring innovation, aims to expand the addressable market in the resilient category [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the scalability of the combined selling team model, particularly in healthcare and education [7] - The company anticipates continued growth driven by strong demand in healthcare and education, supported by macro tailwinds [15][16] - For 2026, the company expects net sales of $1.42 billion to $1.46 billion, with an adjusted gross profit margin of approximately 38.5%-39% [28][29] Other Important Information - The company generated $167.9 million in cash from operating activities in 2025, compared to $148.4 million in 2024 [24] - Capital expenditures for 2025 were $46.2 million, with an expected increase to $55 million in 2026 to support automation initiatives [25] - The board approved an increase in the quarterly dividend from $0.02 to $0.03 per share, reflecting confidence in cash flow generation [26] Q&A Session Summary Question: Can you talk about the One Interface selling strategy? - Management highlighted the success of the combined selling teams in the U.S., with healthcare billings up 21% and nora business up 17% [34] Question: Can you discuss gross margins for 2026? - Management noted that gross margins achieved 38.5%, with expectations for continued expansion driven by automation and efficiency initiatives [36][38] Question: How is the corporate market performing compared to healthcare and education? - Management indicated that the corporate business was flat, with retail business being soft, but healthcare and education showed strong growth [46][47] Question: Can you provide details on the backlog increase? - Management described the backlog as solid and well-distributed across initiatives, providing confidence entering 2026 [50][51] Question: How is SG&A being managed while pursuing growth? - Management emphasized disciplined spending and variable compensation tied to revenue, ensuring efficient use of resources [54][55] Question: What is the impact of tariffs on gross margins? - Management indicated that tariffs diluted gross profit percentage by around 20 basis points in 2025, with an anticipated 50 basis points impact in 2026 [91] Question: Can you provide global billings by category for Q4? - Management reported that corporate was flat, education was up 11.6%, and healthcare was up 11.7% [105]

Financial Data and Key Metrics Changes - In 2025, the company achieved record net sales, adjusted operating income, and adjusted EBITDA, marking the highest levels in its history [4] - Full year net sales totaled $1.39 billion, up 5.4%, with currency-neutral net sales increasing 4.3% [21] - Adjusted gross profit margin increased to 39%, up 187 basis points, driven by favorable pricing and manufacturing efficiencies [22] - Adjusted EPS for the fourth quarter was $0.49, up 44.1% compared to $0.34 [19] Business Line Data and Key Metrics Changes - All three product categories (carpet tile, LVT, and rubber) grew in both price and volume [5] - Global healthcare billings were up 21% year-over-year, with double-digit gains in the Americas and EAAA [14] - Education billings increased 8% for the full year, reflecting the success of expanded collection offerings [15] - Corporate office billings were up slightly for the year, with a focus on gaining share in Class A spaces [15] Market Data and Key Metrics Changes - Currency-neutral net sales in the Americas increased 5.5%, while EAAA saw a 2.4% increase [21] - The company reported a 2% increase in consolidated currency-neutral orders year-over-year [20] - The healthcare and education sectors are experiencing increased investment, driven by aging populations and modernization efforts [15] Company Strategy and Development Direction - The "One Interface" strategy focuses on building strong global functions to support local selling teams and enhancing commercial productivity [4] - The company is committed to sustainability, with initiatives including the launch of a cradle-to-gate carbon negative rubber prototype [12] - The introduction of the noravant product line is expected to open new design possibilities and expand the addressable market [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the scalability of the combined selling team model, particularly in healthcare and education [7] - The company anticipates continued growth in 2026, with a focus on expanding its addressable market through innovative products and pricing strategies [16] - Management acknowledged ongoing macro uncertainties but highlighted a solid order backlog and healthy growth expectations [27] Other Important Information - The company plans to increase capital expenditures to $55 million in 2026 to support automation and productivity initiatives [25] - A quarterly dividend increase from $0.02 to $0.03 per share was approved, reflecting confidence in cash flow generation [26] Q&A Session Summary Question: Can you talk about the One Interface selling strategy? - Management highlighted the success of the combined selling teams, with healthcare billings up 21% and expectations for continued growth through the launch of noravant [35][36] Question: Can you discuss gross margins for 2026? - Management noted that gross margins achieved 38.5%, with expectations for continued expansion driven by automation and efficiency initiatives [38][39] Question: What is the outlook for the corporate market? - Management indicated that the corporate market remains competitive, with growth expectations aligned with strong demand in Class A spaces [48] Question: Can you elaborate on the backlog increase? - Management described the backlog as solid and well-distributed across various initiatives, providing confidence for entering 2026 [51][53] Question: How is the company managing SG&A expenses? - Management emphasized a disciplined approach to SG&A, focusing on investments that drive growth while maintaining efficiency [56][57] Question: What is the impact of tariffs on gross margins? - Management indicated that tariffs had a dilutive impact on gross profit percentage, with expectations for modest inflation in raw materials [95][96]

Financial Data and Key Metrics Changes - 2025 was a record year for the company, with net sales, Adjusted Operating Income, and Adjusted EBITDA reaching their highest levels in history, driven by the One Interface strategy [4] - Full year net sales totaled $1.39 billion, up 5.4%, with currency-neutral net sales increasing 4.3% [18] - Adjusted gross profit margin increased to 39%, up 187 basis points, driven by favorable pricing and manufacturing efficiencies [19] - Adjusted EPS was $1.94, a 33% increase compared to $1.46 [20] Business Line Data and Key Metrics Changes - All three product categories (carpet tile, LVT, and rubber) grew in both price and volume, with global rubber billings up 17% in 2025 [5][12] - Healthcare billings were up 21% year-over-year, while education billings increased 8% [12][13] - Corporate office billings were up slightly, reflecting a competitive market environment [14] Market Data and Key Metrics Changes - Currency-neutral net sales in the Americas increased 5.5%, while EAAA saw a 2.4% increase, indicating improving trends in international markets [18] - The healthcare sector is experiencing increased investment due to aging populations and a focus on preventative care, benefiting the company [13] - The corporate market remains competitive, with Class A spaces in demand, particularly in major cities like New York and San Francisco [44][64] Company Strategy and Development Direction - The One Interface strategy focuses on building strong global functions to support local selling teams, enhancing commercial productivity, and expanding margins through supply chain management [4] - The company is committed to sustainability, with a focus on low-carbon products and innovative solutions like the new Noravant rubber flooring [11][9] - Future growth will be driven by expanding addressable markets through innovative product offerings and maintaining a disciplined approach to SG&A expenses [15][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the scalability of the combined selling team model, particularly in healthcare and education markets [6] - The company anticipates continued growth in 2026, with a focus on leveraging successful strategies and expanding product offerings [14][24] - Management acknowledged ongoing macro uncertainties but remains optimistic about solid orders and a healthy backlog entering 2026 [24] Other Important Information - The company generated $167.9 million in cash from operating activities in 2025, compared to $148.4 million in 2024 [21] - Capital expenditures were $46.2 million in 2025, with expectations to increase to $55 million in 2026 to support automation and productivity initiatives [22] - The quarterly dividend was increased from $0.02 to $0.03 per share, reflecting confidence in cash flow generation [23] Q&A Session Summary Question: Can you elaborate on the One Interface selling strategy? - Management highlighted the success of the combined selling teams and the potential for further expansion in healthcare and education markets [29][30] Question: What are the expectations for gross margins in 2026? - Management indicated that gross margins are expected to continue improving, driven by automation and efficiency initiatives [33][34] Question: How is the corporate market performing compared to healthcare and education? - Management noted that while corporate business was flat, healthcare and education saw significant growth, with ongoing demand in Class A spaces [42][44] Question: Can you provide details on the backlog increase? - Management described the backlog as solid and well-distributed across various initiatives, providing confidence for 2026 [47][49] Question: How is SG&A being managed while pursuing growth opportunities? - Management emphasized disciplined spending and a focus on variable compensation tied to revenue, ensuring efficiency [52][56] Question: What is the impact of tariffs on gross margins? - Management indicated that tariffs had a dilutive impact on gross profit percentage, with expectations for continued monitoring and adjustments [93][94]

Financial Data and Key Metrics Changes - Third quarter net sales were $364.5 million, up 5.9% as reported and 4.2% on a currency-neutral basis compared to the third quarter of 2024, both exceeding expectations [13] - Adjusted gross profit margin was 39.5%, an increase of 208 basis points year over year, driven by favorable pricing and product mix along with manufacturing efficiencies [14] - Adjusted operating income rose to $54.1 million, reflecting a 24.5% year-over-year increase [14] - Adjusted EBITDA for the third quarter was $66.2 million, compared to $53.7 million in the same quarter of 2024 [15] - Adjusted earnings per share increased by 27% to $0.61 from $0.48 in the third quarter of 2024 [15] - The company ended the quarter with $482 million in liquidity and a net leverage ratio of 0.6 times [15] Business Line Data and Key Metrics Changes - The nora rubber segment grew by 20% in the third quarter and is up 19% year to date, driven by the One Interface strategy [5] - Corporate office billings increased by 5% in the third quarter, with year-to-date growth expected [9] - Global healthcare billings surged by 29%, with double-digit gains across both the Americas and EAAA [9] - Education billings saw a slight decline of less than 3% in the third quarter but remain at high single digits year to date [10] Market Data and Key Metrics Changes - In the Americas, currency-neutral net sales increased by 4.1% year over year, while EAAA saw a 4.3% increase [13] - Consolidated currency-neutral orders rose by 2.4% year over year, with the Americas up 1.7% and EAAA up 3.5% [10] Company Strategy and Development Direction - The company is focused on its One Interface strategy, which aims to build strong global functions to support local selling teams and enhance commercial productivity [5] - Investments in automation, productivity, and innovation are being accelerated to strengthen the nora product portfolio and drive long-term growth [6] - The company is preparing to launch a new rubber flooring innovation in early 2026, targeting growth in the healthcare segment [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and disciplined execution, highlighting strong results despite a challenging macro environment [11] - The company is raising its full-year guidance based on year-to-date results, anticipating net sales of $1.375 to $1.390 billion for the fiscal year 2025 [17] Other Important Information - The company received multiple awards for design and sustainability, including Manufacturer of the Year in ED's Net Zero Awards [11] - Tariffs diluted the adjusted gross profit percentage by approximately 30 basis points in the third quarter, with a similar dilution expected in the fourth quarter [16] Q&A Session Summary Question: What drove the sales outperformance this quarter? - Management noted that healthcare was the outperformer, with a 29% increase, exceeding expectations due to a focus on expanding the product portfolio in that segment [21][23] Question: Can you provide more details on investments in nora rubber? - Management confirmed ongoing investments in capacity, productivity initiatives, and innovation to support the growth of the nora rubber business [25][26] Question: How do you view margins going forward? - Management indicated that while they aim for a gross profit margin of 38.5%, they will balance share growth and business expansion [28] Question: Can you provide insights on the tax rate and special items in Q3? - The unusual tax rate of 4.8% was due to a non-cash pickup related to changes in German tax legislation, which required remeasuring deferred tax assets and liabilities [39][40] Question: What is the outlook for capital expenditures in 2026? - Management anticipates a slight increase in capital expenditures, primarily associated with nora rubber and other automation investments [74][76]

Core Insights - Interface, Inc. reported strong third-quarter results for 2025, exceeding expectations with significant year-over-year growth and profitability expansion [2][6] - The company raised its full-year guidance based on robust year-to-date performance, despite acknowledging a challenging global macro environment [8] Financial Performance - Net sales for Q3 2025 reached $364.5 million, a 5.9% increase from $344.3 million in Q3 2024, with a currency-neutral growth of 4.2% [5][6] - Gross profit margin improved by 233 basis points to 39.4% compared to 37.1% in the previous year, driven by favorable product mix and manufacturing efficiencies [4][5] - Operating income rose by 26.5% to $53.4 million, while net income surged by 62.2% to $46.1 million [5][6] - Earnings per diluted share increased to $0.78, reflecting a 62.5% rise from $0.48 in the prior year [5][6] Strategic Initiatives - The "One Interface" strategy is credited with driving growth by enhancing global functions, empowering local sales teams, and streamlining operations [3][6] - The company experienced a 29% increase in Healthcare segment sales and a 5% increase in Corporate Office sales, indicating strong performance across various market segments [3][5] Outlook - Interface raised its full fiscal year 2025 outlook for net sales to a range of $1.375 billion to $1.390 billion, up from the previous estimate of $1.370 billion to $1.390 billion [8] - The adjusted gross profit margin expectation for the full year is now set at 38.5% of net sales, an increase from the prior estimate of 37.7% [8] Segment Performance - In the Americas, net sales increased by 4.0% to $218.6 million, while the EAAA segment saw an 8.8% rise to $145.9 million [7] - Operating income in the Americas grew by 26.8% to $40.4 million, while the EAAA segment's operating income increased by 25.5% to $12.9 million [7]

Financial Data and Key Metrics Changes - Interface reported currency neutral net sales growth of 7% and adjusted earnings per share of $0.60, both exceeding expectations [5][14] - Second quarter net sales totaled $375.5 million, an increase of 8.3% year-over-year, with adjusted gross profit margin at 39.8%, up 402 basis points from the previous year [21][22] - Adjusted operating income rose to $55.9 million, a 41% increase compared to the previous year, while adjusted EBITDA was $64.8 million [22][24] Business Line Data and Key Metrics Changes - The Americas team achieved 11% sales growth, with significant market share gains in carpet tile and rubber, particularly a near 40% growth in Nora Rubber [6][14] - Global education billings increased by 11% year-over-year, while health care billings surged by 28% [15][16] - Corporate office billings returned to growth, up 3% year-over-year, reflecting ongoing investments in workplace refreshes [18] Market Data and Key Metrics Changes - Currency neutral consolidated orders were up 3% year-over-year, with a 2% increase in The Americas and a 4% increase in EAAA [19] - The backlog increased by 24% year-to-date, positioning the company strongly for future sales growth [19][67] Company Strategy and Development Direction - The "One Interface" strategy focuses on building strong global functions to support local selling teams, enhancing productivity, and expanding margins through global supply chain management [5][6] - The company is committed to strategic investments in automation and robotics to improve operational efficiency and support sustainable growth [9][10] - Interface aims to be carbon negative by 2040, having already reduced its carbon footprint significantly across various product lines [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position despite a dynamic macro environment, highlighting strong performance in The Americas and encouraging order growth in EAAA [14][31] - The company raised its full-year guidance based on strong Q2 results, anticipating net sales of $1.37 billion to $1.39 billion for the fiscal year [24][25] - Management emphasized the importance of maintaining a balanced capital allocation strategy while investing in growth and margin expansion [23][40] Other Important Information - Interface repurchased $4.3 million of common stock in the quarter, marking the first repurchase since 2022 [23][39] - The company is focused on expanding its addressable market through product offerings at more approachable price points [7][8] Q&A Session Summary Question: What was the shape of Q2 performance on a similar basis? - Management noted that order growth momentum was strong in April, saw a slight dip in May and June, but picked back up, with July also showing strong order growth [30][31] Question: Can you provide color on government and retail performance in Q2? - Management indicated that almost every market saw growth, including government and retail, with corporate, education, and health care being the primary markets [32][34] Question: What are the business conditions in Australia and Asia? - Management reported strong business conditions in Australia and Asia, with local teams and manufacturing mitigating macro impacts [36][37] Question: What are the plans for capital allocation regarding share repurchases? - Management confirmed that while the primary focus is on investing in the business, they will also return capital to shareholders through share repurchases and dividends [38][40] Question: Is the "One Interface" strategy at full run rate? - Management believes the strategy is still in the early stages, with significant growth potential remaining, particularly in the Nora Rubber business [44][47] Question: What drove the margin performance in the quarter? - Management attributed margin expansion to a combination of pricing, product mix, and manufacturing productivity, with a significant portion driven by operational excellence [48][50] Question: Was there any pull forward of sales in Q2? - Management stated there was no awareness of any sales being pulled forward, although some larger orders in health care may have contributed to lumpiness [59][60] Question: How sustainable are the market share gains? - Management expressed confidence in the sustainability of market share gains, supported by strong product offerings and a focus on expanding into mid-market price points [63][64] Question: What is the timeline for the backlog? - Most of the backlog is expected to ship within the year, with some longer-term contracts included [67] Question: What are the expected returns on investment in international manufacturing assets? - Management indicated that benefits from automation in The Americas will start to be seen in Europe and Australia next year [71] Question: What is the impact of tariffs on gross margins? - The impact of tariffs was largely neutral in the quarter, with some expenses offset by incremental pricing [72] Question: How does the company view the buy versus build decision for growth? - Management emphasized a focus on internal growth and innovation, while remaining open to acquisitions if they align with strategic goals [76]